The prize was awarded on July 3, 2019, during a German congress dedicated to the highlights of the American Cancer Congress 2019. Major contributions to this research work also came from the Fraunhofer scientists Dr. Kathrin Weidele and Dr. Bernhard Polzer. Their highly promising results were published in the International Journal of Cancer in January 2019.
Personalized tumor diagnosis is a focus in the Regensburg-based Fraunhofer ITEM Division of Personalized Tumor Therapy. The scientists of this division develop diagnostic tests and innovative models to enable detection of disseminated cancer cells early in the disease and prediction of the response to therapy of metastatic progenitor cells. They closely collaborate with the Chair of Experimental Medicine and Therapy Research of the University of Regensburg.